Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains
Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains
复制标题
DOI：
10.1006/bbrc.1997.7124
复制
发表时间：
1997-08-28
影响因子：
3.1
通讯作者：
Chambon, P
中科院分区：
文献类型：
--
作者：
Feil, R;Wagner, J;Chambon, P
配体依赖性嵌合Cre重组酶是在培养细胞和小鼠中诱导特异性DNA重排的有力工具。我们在这里报告的一系列嵌合重组酶，每个组成的Cre融合到一个突变的人雌激素受体（ER）配体结合域（LED）的建设和表征。合成的ER拮抗剂4-羟基他莫昔芬（OHT）和ICI 182，780（ICI）分别有效地诱导了两种新的含有人ER LED的G400 V/M543 A/L544 A或G400 V/L539 A/L540 A三重突变的配体依赖性重组酶，但对17 β-雌二醇（E2）不敏感。这两种嵌合重组酶应该可用于有效的时空控制的定点体细胞诱变。(C)北京：科学出版社.
Ligand-dependent chimeric Cre recombinases are powerful tools to induce specific DNA rearrangements in cultured cells and in mice. We report here the construction and characterization of a series of chimeric recombinases, each consisting of Cre fused to a mutated human oestrogen receptor (ER) ligand-binding domain (LED). Two new ligand-dependent recombinases which contain either the G400V/M543A/L544A or the G400V/L539A/L540A triple mutation of the human ER LED are efficiently induced by the synthetic ER antagonists 4-hydroxytamoxifen (OHT) and ICI 182,780 (ICI), respectively, but are insensitive to 17 beta-oestradiol (E2). Both chimeric recombinases should be useful for efficient spatio-temporally controlled site-directed somatic mutagenesis. (C) 1997 Academic Press.